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Copper salt-catalyzed formation of a novel series of
triazole–spirodienone conjugates with potent
anticancer activity†
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Fan Xiao,d Shilong Zheng,bc Yue Chen,e Guangdi Wang*bc and Ling He*a
Copper salt-catalyzed oxidative amination resulted in the formation of a novel series of triazole–
spirodienone conjugates, 4-triazolyl-1-oxa-4-azaspiro[4,5]deca-6,9-dien-3,8-diones and 4-triazolyl-1-
oxa-4-azaspiro[4,5]deca-6,9-dien-8-ones. A single crystal of compound 1p among them was grown and
analyzed by X-ray crystallography. These compounds were evaluated for their antiproliferative activities
against MDA-MB-231, HeLa, A549 and MCF-7 cell lines. Most of them showed moderate to high
anticancer potency in the four cancer cell lines. The discovery of the triazole–spirodienone conjugates
as cytotoxic agents against cancer cells may open up a new field in which these novel small molecules
could be further explored as promising anticancer agents.
Introduction
More than one hundred drugs have been approved by the
United States Food and Drug Administration (USFDA) for
clinical treatment of cancers over the last half century, yet the
search for new chemical entities as potential anticancer agents
continues in the hope that improved pharmaceutical proles
may come from hitherto unknown molecular structures that
encode the keys to greater efficacy and more manageable
adverse side effects. Among numerous drug discovery
approaches such as high-throughout screening, molecular
modeling, and natural compound mimetics, one method may
prove effective that takes pharmacophores important in
existing anticancer agents on which to rationally design
modied structures that may confer a better therapeutic
index.
Quinone is a common moiety of numerous biologically
active molecules, including natural and synthetic anticancer
drugs such as doxorubicin,1 mitoxantrone,2 andaunor-
ubicin3 and mitomycin C.4 The role of the quinone moiety
appears to be important in endowing bioactivities in the
molecules ranging from simple small quinones to large
complex quinoid systems.5–9 Thus the utility of quinone-
containing structures has been extensively explored in
search of anticancer drug candidates, leading to an ever
increasing library of new promising quinones with anti-
cancer activities.10–16 We have previously obtained some
quinone derivatives and conjugates as anticancer agents.17,18
In another previous work on quinones,19 we found that
N-sulfonamide spirodienone derivatives (Fig. 1) demon-
strated moderate cytotoxic activities against HCT-8, Bel-
7402, BGC-823, A549 and A2780 cell lines with IC50 values
in the range of 1.93–51 mM.
The introduction of a 1,2,4-trizole20,21 ring into molecules
has been reported to signicantly increase anticancer activity
or improve the bioavailability and overall pharmacological
prole of a drug candidate.22–26 Indeed, clinically proven anti-
cancer drugs27,28 such as letrozole, vorozole, and anastrozole all
contain a 1,2,4-triazole nucleus which is stable to metabolism
and acts as an important pharmacophore at the active site of
receptors as hydrogen bond acceptor or donor. We hypothesize
that conjugating quinones with a 1,2,4-triazole nucleus may
generate novel molecular entities with desirable anticancer
activities. Therefore, N-sulfonamide-spiro-dienones were
chosen as the lead compound and triazole–spirodienone
conjugates were designed by replacing the sulfonyl functional
group with a 1,2,4 (the relative position of ring nitrogen)-
triazole nucleus (Fig. 1). Herein, we report the synthesis and
anticancer evaluation of the designed triazole–spirodienone
conjugates: 4-triazolyl-1-oxa-4-azaspiro[4,5]deca-6,9-dien-3,8-
diones (1) and 4-triazolyl-1-oxa-4-azaspiro[4,5]-deca-6,9-dien-8-
ones (2).
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Results and discussion
Chemical synthesis
The target conjugates were prepared following the synthetic
scheme as depicted in Fig. 1. The starting materials 1,2,4-tri-
azoles (3) were prepared in an efficient one-pot procedure
including the cyanoimidation of aldehydes and cyclization.29
Following acylation of 3 to form 1,3-substituted-2-chloro-N-(1H-
1,2,4-trizol-5-yl)acetamides (4), the sodium phenoates attacked
4 to provide N-(1,3-disubstituent-1H-1,2,4-triazol-5-yl)-2-
phenoxyacetamides (5). The reduction of 5 gave 1,3-dis-
ubstituent-N-(2-phenoxyethyl)-1H-1,2,4-triazol-5-amines (6).
Subsequently, the key step is the oxidative amination reac-
tion19,30,31 of 5 and 6 leading to their corresponding 4-triazolyl-1-
oxa-4-azaspiro[4,5]deca-6,9-dien-3,8-dione (1) and 4-triazolyl-1-
oxa-4-azaspiro[4,5]deca-6,9-dien-8-one (2) in moderate to high
yields.
The formations reaction of 1a and 2awere taken as an example
for optimization of reaction conditions of the oxidative amination
using the previous work as ref. 19 and 31 The results (Table 1)
show that copper(II), rhodium(II) and ruthenium(II) could be used
as a catalyst for the amination of aromatic ether 5 and 6. Other
metal complexes, such as those of Mn(II), Co(II) and Fe(II) dis-
played poor catalytic activities. At same time, we found that the
yields increased inconspicuously when the loading of [Cu(CH3-
CN)4]ClO4 and Cu(CF3SO2)2 increased from 5% to 20%. In addi-
tion, PhI(OAc)2 and PhI(CF3CO2)2 were employed effectively as
oxidant for the oxidative amination of amides (5) and amines (6).
Finally, the optimized conditions for the formation of triazole–
spirodienones 1a and 2a are in the molar ratio of 1 : 2.5 : 2.5 : 0.1
Fig. 1 N-Sulfonamide spirodienones and synthetic scheme of
designed novel triazole–spirodienone conjugates (1 and 2). Reagents
and conditions: (a) chloroacetyl chloride, (Et)3N, CH2Cl2; (b) R3-
PhONa, DMF; (c) [Cu(CH3CN)4]ClO4, PhI(CF3CO2)2, CH2Cl2, rt; (d)
LiAlH4, AlCl3; (e) Cu(CF3SO2)2, PhI(CF3CO2)2, CH2Cl2, rt.
Table 1 Effect of catalysts and oxidants on the aminationa
Entry Catalyst Oxidant
Yieldb (%)
1a 2a
1 — PhI(CF3CO2)2 — —
2 10% CuCl2 PhI(CF3CO2)2 32 Trace
3 10% CuBr2 PhI(CF3CO2)2 32 Trace
4 10% Cu(CF3SO3)2 PhI(CF3CO2)2 49 57
5 10% Cu(acac)2 PhI(CF3CO2)2 36 28
6 10% Cu(OAC)2 PhI(CF3CO2)2 30 22
7 10% Cu(CF3COCH2COCF3)2 PhI(CF3CO2)2 36 29
8 10% Cu[(CH3CN)4]ClO4 PhI(CF3CO2)2 94 40
9 5% Rh2(OAc)4 PhI(CF3CO2)2 33 Trace
10 5% Ru(TTP)CO PhI(CF3CO2)2 44 Trace
11 10% Cu(CF3SO3)2 PhI(OAc) 2 35 51
12 10% Cu(CF3SO3)2 PhI]O 27 Trace
13 10% Cu[(CH3CN)4]ClO4 PhI(OAc) 2 45 47
14 10% Cu[(CH3CN)4]ClO4 PhI]O 30 Trace
a Substrate(1 mmol), oxidant (2.5 mmol), Al2O3(2.5 mmol); CH2Cl2 as
solvent, room temperature, 4 A molecular sieve. b Isolated yield based
on the amount of compounds 1a and 2a consumed.
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 9412–9416 | 9413
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of substrate : PhI(CF3CO2)2 : Al2O3 : Cu[(CH3CN)4]ClO4 for 1a or
(Cu(CF3SO2)2) for 2a at room temperature. Next, the reaction
conditions of 1a and 2a were expanded to the formation reactions
of all triazole–spirodienones 1 and 2, respectively. Thus, twenty
four triazole–spirodienone 1 and 2 were obtained in 36–94% yield
(Fig. 1) from corresponding 2-phenoxy-ethyl-acet-N-2,3,5-tri-
azoleamides and 2-phenoxy-ethyl-ethyl-N-2,3,5-triazoleamines.
In entry, the effects of the substituents on the oxidative
amidation reaction were noticed that the electron-donating
groups sped the oxidative amination reaction of the aromatic
ether derivatives (5 and 6) and the electron-withdrawing
substituents resulted in moderate yields of the reaction,
thereby, the reaction rates rely on the easy of oxidation of the
substrate and the yields of triazole–spirodienone (1 and 2) are
linked with the activity of the nitrogen sources, especially, the
effect of N–H dissociation energies of the nitrogen source.
To conrm the structures of triazole spirodienone conju-
gates, a single crystal of 1p was grown and analyzed by X-ray
crystallography (the detailed crystal data are provided in the
ESI†). The ORTEP structure plot of 1p is displayed in Fig. 2.
The effect of substituent was investigated using different
substituted aromatic ether derivatives as substrates under
strictly identical condition. Interestingly, we notice that the
reaction of thesemethoxy group substituent in themeta-position
gave only two corresponding six-membered heterocyclic prod-
ucts 3a and 3b in 53% and 24% yield respectively (Scheme 1).
A mechanism is proposed in Scheme 2 for the oxidative
amination reaction of the aromatic ether with b-NH–imidazole
based on the mechanisms proposed originally for the amina-
tion by Antonchick32 and Chiba.33 Initially ditriuoro-
acetoxyiodobenzene reacts with the amide to give interme-
diate A, which is then transformed into intermediate B through
an oxidative insertion of N–I bond by copper(II). The reductive
elimination of intermediate C releases copper(I) salt, triuoro-
acetic acid and iodobenzene, leading to nal product 4-(1,3-
diphenyl-1H-1,2,4-triazol-5-yl)-1-oxa-4-azaspiro[4.5]-deca-6,9-
diene-3,8-dione (1). And the 4-(1,3-diphenyl-1H-1,2,4-triazol-5-
yl)-1-oxa-4-azaspiro[4.5]deca-6,9-diene-8-one (2) was obtained
in similar mechanisms.
Antiproliferation activity against a panel of cancer cell lines
All of triazole–spirodienone conjugates (1 and 2) were examined
for in vitro antiproliferation activities against a triple negative
human breast cancer cell line, MDA-MB-231, an ER + human
epithelial mammary carcinoma cell line, MCF-7, an invasive
cervical cancer cell line, HeLa, and a metastatic non-small cell
lung cancer cell line, A549. Table 2 displayed the IC50 values of 1
and 2 against these four cell lines. Moderate to high anti-
proliferative activities were observed in most of 1 and 2 deriv-
atives, with IC50 values ranging from low nanomolar
concentration to micromolar concentration. The triazole–spi-
rodienone conjugates inhibited cancer cell growth in a dose-
dependent manner in all four cancer cell lines tested, and
appear to exert a greater inhibitory effect on MDA-MB-231 cells
in particular. Notably, 4-triazolyl-1-oxa-4-azaspiro[4,5]-deca-6,9-
dien-3,8-diones (1) were generally stronger cell growth inhibi-
tors than the corresponding 4-triazolyl-1-oxa-4-azaspiro[4,5]
deca-6,9-dien-8-ones (2). The only structural difference
between 1 and 2 is the extra carbonyl group on 3-position of the
spirodienone ring of 1, suggesting that introduction of a 3-one
functional group at the spiro-ring increased the antiprolifera-
tion activity against cancer cells.
Cytotoxicity towards MCF-10A normal mammary epithelial
cells
Seven of the most promising triazole–spirodienone conjugates
(1a, 1d–f, and 1i–k) were selected for further evaluation of
toxicity in normal mammary epithelial cells, MCF-10A. At 10
mM, all the compounds were found to be signicantly toxic
towards MCF-10A cells, with toxicities moderating at a lower
dosage of 1 mM. At both doses of 1 and 10 mM, doxorubicin,
a widely used anticancer drug in clinic, was found to be much
more toxic to normal cells than any of the selected triazole–
spirodienone conjugates (the detailed data see ESI†). This
observation is encouraging because the novel structural motif
of triazole–spirodienone conjugates may offer a better separa-
tion of desired tumor toxicity and toxicity to normal cells.
Fig. 2 ORTEP plot of molecular structure of 1p.
Scheme 1 The reaction results of m-methoxy substituted aromatic
ether derivatives as substrates.
Scheme 2 Proposed mechanism for oxidative amination.
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Apoptosis of HeLa cells
We performed a caspase 3/7 activation assay for compounds 1b,
1i, 1f and 1p using uorescence microscopy. HeLa cells were
treated with four selected triazole–spirodienone conjugates at 1.0
mM or vehicle for 24 hours. In this assay, uorescence signal was
related to the degree of caspase 3/7 activation and hence
apoptosis induced by the treatment. As shown in Fig. 3, untreated
cells showed minimal uorescence, while treated cells exhibited
signicant increase in uorescence (shown in green) indicating
the prevalence of apoptosis of HeLa cells. These observations
strongly suggest that triazole–spirodienone conjugates inhibited
HeLa cells proliferation by triggering apoptosis.
Conclusions
Copper salt-catalyzed oxidative amination resulted in the
formation of novel triazole–spirodienone conjugates, 4-triazolyl-
1-oxa-4-aza-spiro[4,5]deca-6,9-dien-3,8-diones (1) and 4-triazolyl-
1-oxa-4-aza-spiro[4,5]deca-6,9-dien-8-ones (2) which were evalu-
ated for their antiproliferative activities against MDA-MB-231,
HeLa, A549 and MCF-7 cell lines. Most of them showed
moderate to high anticancer potency in the four cancer cell lines.
Moreover, 4-triazolyl-1-oxa-4-azaspiro[4,5]deca-6,9-dien-3,8-diones
(1) were found to exhibit superior anticancer activities compared
to 4-triazolyl-1-oxa-4-azaspiro[4,5]deca-6,9-dien-8-ones (2). The
cytotoxicities of 1a, 1d–f, and 1i–k toward non-cancerous cells
(MCF-10A) were measurable, but much less severe than that of
doxorubicin, a known and widely used chemotherapy agent. Our
study represents the rst report on the preparation and biological
evaluation of the novel triazole–spirodienone conjugates as
potential anticancer agents. The analogs (1) are promising lead
compounds on which further optimization of structure–activity
relationships may lead to therapeutically useful new chemical
entities for clinical treatment of cancer. Preliminary study on the
mode of action suggests that the triazole–spirodienone conjugates
inhibited cancer cell proliferation by triggering apoptosis, with
more in-depth mechanistic studies under way in our laboratories.
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